Trending...
- Tampa-Based Digital Marketing Agency Launches New Website to Help Local Businesses Grow Online
- Global Families Turn to Young Travelers Concierge Amid Rising Safety Concerns in the U.S
- Meditech International Inc. and Los Angeles Rams Continue Strategic Partnership to Enhance Athlete Performance and Recovery
CHICAGO, July 31, 2024 ~ At the ADLM 2024 conference, formerly known as the AACC Annual Scientific Meeting & Clinical Lab Expo, researchers from Revvity's Euroimmun will be presenting data on a new test that could potentially improve outcomes for patients with Alzheimer's disease. This test predicts whether patients are genetically predisposed to side effects from anti-amyloid drugs, a promising new class of Alzheimer's therapeutics.
The use of anti-amyloid drugs has been a major breakthrough in the treatment of Alzheimer's disease. Last year, lecanemab became the first medication ever to receive FDA approval for slowing the progression of the disease. Since then, more anti-amyloid drugs have also received FDA approval, offering hope to individuals with this condition. However, concerns have been raised about the safety of these drugs, with the FDA warning that they can cause brain swelling and/or bleeding. This side effect is known as amyloid-related imaging abnormalities (ARIA), and while it is usually mild, it can lead to death in rare cases. The risk of ARIA is higher in individuals who have specific variants of the APOE gene, which is implicated in many forms of Alzheimer's. As a result, the FDA recommends that patients undergo genetic testing before taking anti-amyloid drugs.
More on illi News
The team at Revvity's Euroimmun has developed a new PCR-based test that can determine if a patient has a high-risk combination of APOE gene variants (also known as a genotype). This method tests for all six possible APOE genotypes simultaneously, allowing for quicker processing by laboratories and ensuring that patients receive results faster. To evaluate its performance, the researchers used this test to analyze 100 blood samples from Alzheimer's patients and 10 samples from healthy blood donors. They also analyzed the same samples using a CE-IVD-marked APOE test and bidirectional Sanger sequencing method and compared the results from all three methods. The results were consistent in all 110 cases, demonstrating that the Revvity's Euroimmun test accurately detects a patient's APOE genotype with 100% accuracy.
Dr. Maite Sabalza, senior scientific affairs manager at Revvity's Euroimmun, explained the importance of this new test in light of the recent advancements in anti-amyloid drugs. "There has been a lot of progress with new drugs approved by the FDA, and as a result, diagnostic assays need to be updated to be able to test for the consequences of these drugs," she said. "There is a need to screen patients before receiving treatment, and if they are positive for a high-risk APOE genotype, doctors can discuss the possibility of stopping or monitoring the treatment or trying something different."
More on illi News
The team at Revvity's Euroimmun is hopeful that their test will become an essential part of the care Alzheimer's patients receive before starting anti-amyloid therapy. "We want to help these patients," Dr. Sabalza stated.
The presentation of this research will take place during the scientific poster session on Wednesday, July 31st from 9:30 a.m. to 5 p.m., with presenting authors available for questions from 1:30 p.m. to 2:30 p.m. The session will be held in the Poster Hall on the Expo show floor at McCormick Place in Chicago.
For media members interested in attending ADLM 2024, registration is free and can be completed online at https://xpressreg.net/register/adlm0824/media/l.... This conference offers valuable insights into cutting-edge research and advancements in laboratory medicine and diagnostics.
The use of anti-amyloid drugs has been a major breakthrough in the treatment of Alzheimer's disease. Last year, lecanemab became the first medication ever to receive FDA approval for slowing the progression of the disease. Since then, more anti-amyloid drugs have also received FDA approval, offering hope to individuals with this condition. However, concerns have been raised about the safety of these drugs, with the FDA warning that they can cause brain swelling and/or bleeding. This side effect is known as amyloid-related imaging abnormalities (ARIA), and while it is usually mild, it can lead to death in rare cases. The risk of ARIA is higher in individuals who have specific variants of the APOE gene, which is implicated in many forms of Alzheimer's. As a result, the FDA recommends that patients undergo genetic testing before taking anti-amyloid drugs.
More on illi News
- This Budget Didn't Break the System—It Exposed the Truth
- Statement From EWTN Chairman & CEO Michael P. Warsaw On The Election of Pope Leo XIV
- NBA Champion Lamar Odom Launches Anti-Addiction Meme Coin, Ushering in a Disruptive Innovation in Web3
- Mentor Agile Empowers Illinois Residents with Free Access To Product Management Training
- Midwest Pond Features & Landscapes Hits 100 Cleanouts This Spring, Expands Services Across Chicago
The team at Revvity's Euroimmun has developed a new PCR-based test that can determine if a patient has a high-risk combination of APOE gene variants (also known as a genotype). This method tests for all six possible APOE genotypes simultaneously, allowing for quicker processing by laboratories and ensuring that patients receive results faster. To evaluate its performance, the researchers used this test to analyze 100 blood samples from Alzheimer's patients and 10 samples from healthy blood donors. They also analyzed the same samples using a CE-IVD-marked APOE test and bidirectional Sanger sequencing method and compared the results from all three methods. The results were consistent in all 110 cases, demonstrating that the Revvity's Euroimmun test accurately detects a patient's APOE genotype with 100% accuracy.
Dr. Maite Sabalza, senior scientific affairs manager at Revvity's Euroimmun, explained the importance of this new test in light of the recent advancements in anti-amyloid drugs. "There has been a lot of progress with new drugs approved by the FDA, and as a result, diagnostic assays need to be updated to be able to test for the consequences of these drugs," she said. "There is a need to screen patients before receiving treatment, and if they are positive for a high-risk APOE genotype, doctors can discuss the possibility of stopping or monitoring the treatment or trying something different."
More on illi News
- Aureli Construction Sets the Standard for Seamless Home Additions in Greater Boston
- ScreenPoints Puts Film Investors in the Credits—and in the Money With New FinTech Platform
- Beyond Finance Wins Gold Stevie® Award for Customer Service Department of the Year in 23rd Annual American Business Awards
- Pathways to Adulthood Conference May 17 at Melville Marriott Honoring NYS Assembly Member Jodi Giglio, Suffolk County Legislator Nick Caracappa
- Adster Techologies awarded US Patent for breakthrough innovation in reducing latency in Ad Serving
The team at Revvity's Euroimmun is hopeful that their test will become an essential part of the care Alzheimer's patients receive before starting anti-amyloid therapy. "We want to help these patients," Dr. Sabalza stated.
The presentation of this research will take place during the scientific poster session on Wednesday, July 31st from 9:30 a.m. to 5 p.m., with presenting authors available for questions from 1:30 p.m. to 2:30 p.m. The session will be held in the Poster Hall on the Expo show floor at McCormick Place in Chicago.
For media members interested in attending ADLM 2024, registration is free and can be completed online at https://xpressreg.net/register/adlm0824/media/l.... This conference offers valuable insights into cutting-edge research and advancements in laboratory medicine and diagnostics.
Filed Under: Business
0 Comments
Latest on illi News
- $56.7 Million Announced in Q1 2025 with Revenue Growth and Progress Toward NASDAQ Uplisting for AI Marketing Company: IQSTEL, Inc. Stock Symbol: IQSTD
- SAVVY MINING raised $500 million and launched BTC.XRP.DOGE cloud mining, increasing investors' returns by 30%
- New National Nonprofit Launches to Capture Firsthand Accounts of Adoption Stories
- The Tide Project Opens at Biennale Architettura 2025 in Venice Amplifying Youth Voices
- Wall Street analysts say BTC.XRP.DOGE cloud mining company SIX MINING is expected to achieve a 5-fold increase, allowing users to easily mine BTC
- Gen X Takes The Reins: New Book Guides Caregivers Juggling Parents, Kids, And Grandkids With Humor And Heart
- Naperville Welcomes Top Global Leaders Through Americas Competitiveness Exchange Visit
- Fray Fitness Launches Memorial Day Sale and Veteran Organization Giveaway
- ABM for Good™ Launches First Project with Build Change
- Local Nonprofit Files Lawsuit Against Trump Administration's Attack on AmeriCorps
- Pregis Honors Partners Driving Measurable Impact with Annual Pregis Purpose Awards
- ImagineX, in Collaboration with Qualys, Launches New mROC Services to Transform Enterprise Cyber Risk Management
- Ditch Micromanagement: New Leadership Book for Results-Driven, Accountability-Based Teams
- Jay Tapp was named Managing Director in British Columbia
- Hubei Heavy Equipment Makes a Striking Appearance at CIMT and Competes with International Brands
- 20 Patents Issued Worldwide, Cementing Company Leadership. First Ever Cable-Free 12-Lead ECG: HeartBeam, Inc. (Stock Symbol: BEAT)
- NASDAQ Uplisting for Higher Market Exposure and Wide Corporate Benefits to AI Boosted Marketing Company On Track Towards $1 Billion Revenue by 2027
- AAR announces investor conference schedule for May and June 2025
- Congressional Men's Health Caucus Shows Bipartisan Consensus and Focus on Prevention, Mental Health, and Closing the Lifespan Gap
- The Alternative AI Architecture That Creates Certainty and Trust - No More Guesses.